Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,60
KB-2,67
PKN121,28121,5-3,67
Msft-2,77
Nokia6,3266,384-9,16
IBM0,25
Mercedes-Benz Group AG37,29537,49-1,69
PFE-0,51
21.11.2026 2:00:20
Indexy online
AD Index online
select
AD Index online
 

  • 20.11.2026
Ocular Therapeutix (NASDAQ Cons)
Závěr k 20.11.2026 Změna (%) Změna (USD) Objem obchodů (USD)
5,57 -4,95 -0,29 10 820 743
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace:
Popis společnosti
Obecné informace
Název společnostiOcular Therapeutix Inc
TickerOCUL
Kmenové akcie:Ordinary Shares
RICOCUL.O
ISIN-
Poslední známé roční výsledky31.12.2025
Poslední známé čtvrtletní výsledky30.09.2026
Počet zaměstnanců k 31.12.2025 325
Akcie v oběhu k 06.11.2026 220 022 840
MěnaUSD
Kontaktní informace
Ulice15 Crosby Drive
MěstoBEDFORD
PSČ01730
ZeměUnited States
Kontatní osobaBill Slattery
Funkce kontaktní osobyIR Contact Officer
Telefon13 026 744 089
Fax13026745266

Business Summary: Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.
Financial Summary: BRIEF: For the nine months ended 30 September 2026, Ocular Therapeutix Inc revenues decreased 4% to $37.1M. Net loss increased 30% to $262.2M. Revenues reflect ophthalmology segment decrease of 67% to $12.9M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.14847 to -$1.16586.
Odvětvová klasifikace
TRBC2009Medical Equipment / Supplies / Distribution
TRBC2012Pharmaceuticals (NEC)
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Research and Development in Biotechnology
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace:
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Executive Chairman of the Board, President, Chief Executive OfficerPravin Dugel6215.04.202421.02.2024
Chief Financial OfficerJason Robins5010.06.202620.01.2026
Chief Operating OfficerDonald Notman6620.01.202625.09.2017
Chief Scientific OfficerJeffrey Heier6521.02.202421.02.2024
Chief Development OfficerPeter Kaiser5901.10.202421.02.2024
Global Chief Commercial OfficerDavid Robinson67
Chief Business OfficerNamrata Saroj52
Chief Medical OfficerNadia Waheed49
Chief Legal Officer and SecretaryTodd Anderman4407.10.202407.10.2024